Get the Stockscreener App
2.07
0.00%
0.00
After Hours:
2.07
Xortx Therapeutics Inc stock is traded at $2.07, with a volume of 13,134.
It is up +0.00% in the last 24 hours and down -6.33% over the past month.
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.
See More
Previous Close:
$2.07
Open:
$2.165
24h Volume:
13,134
Relative Volume:
0.01
Market Cap:
$3.58M
Revenue:
-
Net Income/Loss:
$-2.77M
P/E Ratio:
-0.7822
EPS:
-2.6464
Net Cash Flow:
$-2.69M
1W Performance:
-5.91%
1M Performance:
-6.33%
6M Performance:
-31.00%
1Y Performance:
-54.01%
1-Day Range:
$2.06
$2.20
1-Week Range:
$2.06
$2.28
52-Week Range:
$1.725
$7.05
Xortx Therapeutics Inc Stock (XRTX) Company Profile
Compare XRTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XRTX
Xortx Therapeutics Inc
|
2.07 | 3.76M | 0 | -2.77M | -2.69M | -2.6464 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Xortx Therapeutics Inc Stock (XRTX) Latest News
Why XORTX Therapeutics Inc stock is skyrocketing today - Wealth Awesome
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
XORTX Therapeutics Company Profile & Introduction - Moomoo
XORTX Therapeutics Inc (XRTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
XORTX Therapeutics Inc (XRTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
XORTX Therapeutics Inc (XRTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
XORTX Therapeutics Inc (XRTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
XORTX Therapeutics Inc (XRTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
XORTX Therapeutics Inc (XRTX) Institutional Confidence - TradingKey
XORTX Therapeutics Q1 2024 Earnings: Significant EPS Miss Reflects R&D Investment, Stock Gains Despite Loss - newsline.com
XORTX Therapeutics Inc (XRTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
XORTX Therapeutics Inc (XRTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
XORTX Therapeutics Inc (XRTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
XORTX Therapeutics (XRTX) Slips 0.68% as Traders Eye Key Support at $2.06Covered Call ETF - newsline.com
XORTX Therapeutics appoints Mika Grasso as co‑CEO - MSN
XORTX Therapeutics Appoints Mika Grasso as Co-CEO; Voluntarily Delisting from the TSX Venture Exchange - marketscreener.com
XORTX Therapeutics Inc. Announces Appointment of Mika Grasso to Co-CEO - marketscreener.com
XORTX Therapeutics Providing Corporate Update and Appoints Mika Grasso as Co-CEO - marketscreener.com
XORTX Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16] - Moomoo
XORTX Therapeutics (NASDAQ: XRTX) refocuses on gout program and appoints co-CEO - Stock Titan
A 28-year-old co-CEO and XORTX's $700M gout push in the US - Stock Titan
XORTX to Voluntarily Delist from TSX Venture Exchange, Maintain Nasdaq Listing - The Globe and Mail
XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange - The Manila Times
XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange | Associated Press | syndication news - Enidnews.com
XORTX Therapeutics (NASDAQ: XRTX) to voluntarily delist from TSX Venture - Stock Titan
XRTX Stock Chart | XORTX THERAPEUTICS INC (NASDAQ:XRTX) - ChartMill
XORTX Therapeutics (XRTX) Slides Over 3% as Biotech Stock Tests Key Support LevelsTrend Reversal Picks - newsline.com
XORTX Therapeutics (XRTX) Holds Near Support in Quiet Trading SessionSkew Index - thelegaladvocate.com
XORTX Therapeutics (XRTX) Edges Higher as Stock Holds Above Key SupportAnalyst Upgrade Stocks - newsline.com
XORTX Therapeutics (XRTX) Gains 1.27% as Shares Test Key Resistance LevelLong Short Pair - dars.gov.et
XRTX News | XORTX THERAPEUTICS INC (NASDAQ:XRTX) - ChartMill
XORTX Therapeutics Q1 2024 Earnings: Steep EPS Miss Highlights Pre‑Revenue Biotech HurdlesGuidance Upgrade Report - newsline.com
XORTX Raises US$5 Million in Public Offering to Fund Kidney and Gout Drug Programs - The Globe and Mail
XORTX Therapeutics Raises US$5 Million Via Public Offering - marketscreener.com
XORTX Announces Closing of US$5 Million Public Offering - markets.businessinsider.com
XORTX Therapeutics (NASDAQ: XRTX) closes US$5M share and pre-funded warrant deal - Stock Titan
XORTX raises US$5M, earmarks US$2.5M for investor marketing - Stock Titan
E.F. Hutton & Co. Serves as Exclusive Placement Agent on XORTX Therapeutics Inc. $5 Million Public Offering - The Manila Times
XORTX Therapeutics Inc.Common Shares (NQ: XRTX - FinancialContent
XORTX Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
XORTX Therapeutics Inc expected to post a loss of C$1.64 a shareEarnings Preview - TradingView
Here are the top movers in Friday's session. - ChartMill
XORTX (NASDAQ: XRTX) raises ~$4.7M via share sale and pre-funded warrants - Stock Titan
XRTX Announces Public Offering of Shares - GuruFocus
XORTX Therapeutics Raising US$5 Million in a Public Offering; Shares Down 8.9% - marketscreener.com
XORTX (NASDAQ: XRTX) prices US$5M public equity and warrant deal - Stock Titan
Xortx announces US$5 million public offering - marketscreener.com
XORTX Announces US$5 Million Public Offering - The Manila Times
XORTX Announces US$5 Million Public Offering | Associated Press | syndication news - Enidnews.com
[EFFECT] XORTX Therapeutics Inc. SEC Filing - Stock Titan
Xortx Therapeutics Inc Stock (XRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):